August 2026– date –
-
Japan’s Reprocell and University Announce Joint Development of iPSC Differentiation Protocol, Enhancing Cell Therapy Product Uniformity and Scalability
Reprocell / University Announcement Japan Overview Japanese regenerative medicine company Reprocell, in collaboration with a prominent university research lab, announced the joint development of a novel protocol for high-efficiency diffe... -
Exosome Therapeutics Firm Unveils Advanced Platform, Pipeline Progress Targeting Regenerative Medicine and Enhanced Drug Delivery
Company Disclosures USA Overview An exosome-based therapeutics company has detailed significant pipeline advancements and its cutting-edge technology platform at a recent investor briefing. The presentation particularly emphasized exosom... -
Automated GMP Facility Launched, Supercharging Scalable Production for Off-the-Shelf Cell Therapies
Company Announcement / Specialized Media International Overview A new, state-of-the-art GMP facility dedicated to commercial-scale allogeneic cell therapy manufacturing has commenced operations. This facility leverages advanced automatio... -
Pharma Giant Acquires Gene-Editing Pioneer, Bolstering Pipeline and Redefining R&D
Specialized Media USA Overview A leading pharmaceutical company has acquired a smaller biotechnology firm specializing in innovative gene-editing platforms. This strategic move aims to integrate cutting-edge gene therapy modalities into ... -
FDA Bestows RMAT Status on iPSC-Derived Cell Therapy for Intractable Disease, Poised to Accelerate Clinical Development
Company Announcement / Specialized Media USA Overview A regenerative medicine firm has announced its iPSC-derived cell therapy program for an intractable disease has received Regenerative Medicine Advanced Therapy (RMAT) designation from... -
FDA Issues Draft Guidance for Long-Term Follow-Up of Gene Therapies, Establishing Industry Standards for Safety and Efficacy
STAT News USA Overview The U.S. Food and Drug Administration (FDA) has released new draft guidance for the long-term safety and efficacy follow-up of approved gene therapy products. This guidance aims to establish industry standards for ... -
BioPharma Dive Features Real-World Evidence Analysis of Approved CAR-T Therapies, Unveiling New Insights into Subgroup Efficacy and Long-Term Safety
BioPharma Dive USA Overview BioPharma Dive published an in-depth analysis of post-market real-world data for approved CAR-T cell therapies. The article reveals novel insights into efficacy within specific patient subgroups and the long-t... -
Company Announces Positive Safety and Early Efficacy Signals in Phase 1 Clinical Trial of iPSC-Derived Retinal Cell Therapy, Aims for Phase 2 This Year
Endpoints News USA Overview A cell therapy development company has reported favorable safety data and initial efficacy signals from its ongoing Phase 1 clinical trial of an iPSC-derived cell therapy for a specific ocular disease. This th... -
Major Pharmaceutical Company Forges Strategic Alliance with Gene-Editing Biotech to Accelerate Multi-Disease In Vivo Gene Editing Therapy Development
Fierce Biotech USA Overview A leading pharmaceutical company announced a strategic partnership with a biotech firm specializing in gene-editing technology. This alliance aims for the co-development of in vivo gene-editing therapies acros... -
Stealth Cell Therapy Startup Secures Series B, Accelerating iPSC-Derived Neurodegenerative Candidate Towards IND
Specialized Media / Company Announcement USA Overview An undisclosed cell therapy startup has successfully closed its Series B funding round, securing substantial capital. This investment will accelerate preclinical development and suppo...
